Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
Bio2RDF identifier
NCT00035932
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00035932
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
baseline [clinicaltrials_vocabulary:baseline]
brief summary [clinicaltrials_vocabulary:brief-summary]
The purpose of this stu ...... RTV and TDF and a nucleoside.
brief title [clinicaltrials_vocabulary:brief-title]
Atazanavir (BMS-232632) in Com ...... ucleoside in Subjects With HIV
clinical result [clinicaltrials_vocabulary:clinical-result]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
completion date [clinicaltrials_vocabulary:completion-date]
2009-03-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2002-05-06T00:00:00Z
firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]
2010-10-14T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2010-11-29T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct alias [clinicaltrials_vocabulary:nct-alias]
NCT00028054
nct id [clinicaltrials_vocabulary:nct-id]
NCT00035932
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Phase III Open Label Atazanavi ...... ucleoside in Subjects With HIV
org study id [clinicaltrials_vocabulary:org-study-id]
outcome [clinicaltrials_vocabulary:outcome]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
participant flow [clinicaltrials_vocabulary:participant-flow]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2003-07-01T00:00:00Z
reported events [clinicaltrials_vocabulary:reported-events]
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2001-11-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2010-11-01T00:00:00Z
identifier
clinicaltrials:NCT00035932